Many innovative and curative therapies are coming to market for rare blood disorders, but will they be available to Canadian patients?
What is the role of patient organizations in ensuring access to innovative and curative therapies?
These questions and more will be explored over two days of interactive and engaging sessions.
Join fellow patients, health care providers, industry professionals, and policymakers as current regulatory and reimbursement policies are reimagined to ensure timely and equitable access to innovative therapies for those living with rare blood disorders.
Each session follows an engaging 20-20-20 format: 20 minutes of science/clinical/regulatory presentations, 20 minutes of community/patient perspectives, and 20 minutes of discussion. There will be lots of opportunities for participation through chats, question submissions, and polls.